In-Vitro, In-Vivo and Licensing - Clinical Research Informer

Ginkgo Bioworks partners with WARF for new GD2 CAR T-cell therapies

Pharmaceutical Technology

APRIL 14, 2023

WARF is the patenting and licensing organisation for the University of Wisconsin–Madison in the US. All the new GD2 CAR designs developed through the partnership will be validated via in vitro screens and in vivo murine models. Topic sponsors are not involved in the creation of editorial content.

In-Vivo

In-Vivo Gene Therapy In-Vitro Engineer

Nuvectis Pharma receives IND approval from FDA for NXP900

Pharmaceutical Technology

MAY 16, 2023

Nuvectis has licensed the exclusive global rights to NXP900 from the University of Edinburgh in Scotland, UK. NXP900 plus Osimertinib in vitro showed a possible ability to reverse acquired resistance to these drugs in non-small cell lung cancers. The approval also includes clearance for a Phase I clinical trial protocol of NXP900.

In-Vivo

In-Vivo In-Vitro Clinical Trials Clinical Trials

Betta to commercialise C4 Therapeutics’ CFT8919 in greater China

Pharmaceutical Technology

MAY 31, 2023

C4 Therapeutics has entered an exclusive licensing agreement with Betta Pharmaceuticals to develop and commercialise CFT8919 across the greater China region. Betta will be responsible for the development, manufacture and commercialisation of CFT8919 in the licensed territories.

In-Vivo

In-Vivo Bioavailability In-Vitro Licensing

Blenrep Combination Extends Survival in Relapsed Multiple Myeloma

XTalks

DECEMBER 13, 2024

XTALKS WEBINAR: Enhance Early Biomarker Discovery: Translating In Vitro and In Vivo Multi-Omics Oncology Data Live and On-Demand: Thursday, January 16, 2025, at 11am EST (4pm GMT/UK) Register for this free webinar to learn how to harness the full potential of multi-omics data and advanced patient models to drive early biomarker discovery.

Antibody

Antibody In-Vivo Trials In-Vitro

Could CRISPR cure HIV? US biotech Excision raises $60m to find out

pharmaphorum

FEBRUARY 19, 2021

The company, which has licensed the CRISPR-based technology from Philadelphia’s Temple University, says it has already produced a functional cure for HIV that works in animals and wants to develop the technology in humans. We have proven the technology and candidate programs in vitro and in vivo in both small animal models and primate models.

Gene Editing

Gene Editing In-Vivo DNA In-Vitro

Merck will assess Quris’ AI ‘patient-on-a-chip’ drug safety

pharmaphorum

FEBRUARY 13, 2022

Quris’ BioAI safety prediction platform – which is based on human tissue samples on chips, nanosensors and machine learning – will be compared to traditional in vitro and in vivo laboratory techniques for spotting toxicity.

Drugs

Drugs In-Vivo In-Vitro Pharma Companies

AvantGen Announces Licensing of Its Anti-SARS-CoV-2 Antibodies to IGM Biosciences for COVID-19 Therapy Development

The Pharma Data

JANUARY 11, 2021

a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

Antibody

Antibody Licensing Licensing Development

ViGeneron signs global collaboration agreement for ophthalmic gene therapy development

The Pharma Data

JANUARY 4, 2021

05, 2021 (GLOBE NEWSWIRE) — ViGeneron GmbH , a gene therapy company, today announced a global collaboration and licensing agreement with Biogen Inc. Within the collaboration, ViGeneron will optimize and validate in vitro therapeutic candidates for an undisclosed target to treat inherited eye disease. MUNICH, Germany, Jan.

Gene Therapy

Gene Therapy Gene Development In-Vivo

Separating the Hype from the Hyperbole Surrounding FDORA’s Alternatives to Animal Testing under the FD&C Act

FDA Law Blog

FEBRUARY 2, 2023

The law defines this term to mean “a test conducted in vitro, in silico, or in chemico, or a nonhuman in vivo test that occurs before or during the clinical trial phase of the investigation of the safety and effectiveness of a drug.” Tobolowsky & Charles G. FDORA § 3209(a)(1). FDORA § 3209(a)(2). 42 U.S.C. § 262(k)(2)(A)(i)(I).

Clinical Trials

Clinical Trials Clinical Trials In-Vivo In-Vitro

Evusheld long-acting antibody combination recommended for approval in the EU for the pre-exposure prophylaxis (prevention) of COVID-19

The Pharma Data

MARCH 25, 2022

There is a growing body of evidence from multiple independent in vitro and in vivo (animal model) studies supporting the potential of Evusheld to protect against the BA.1, 7,8) This study also showed Evusheld reduced viral burden and limited inflammation in the lungs (in vivo) across all Omicron variants.(7).

Antibody

Antibody In-Vivo Medicine Vaccine

Evusheld long-acting antibody combination approved in the EU for pre-exposure prophylaxis (prevention) of COVID-19 in a broad population

The Pharma Data

MARCH 29, 2022

There is a growing body of evidence from multiple independent in vitro and in vivo (animal model) studies supporting the potential of Evusheld to protect against the BA.1, 6,7 This study also showed Evusheld reduced viral burden and limited inflammation in the lungs (in vivo) across all Omicron variants.6. Christoph D.

Antibody

Antibody In-Vivo Vaccine Vaccination

Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer

The Pharma Data

JANUARY 12, 2021

Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g. Previously, he held roles as CMO at Trimeris Inc.

Life Science

Life Science Antibody In-Vivo In-Vitro

Innovative Companies Diving into The Neuro Market Ahead of 2021

The Pharma Data

DECEMBER 9, 2020

Atlas cofounded, seeded and incubated Vigil, with pre-clinical stage assets in-licensed from Amgen Inc., Vigil’s $50 million Series A financing, completed this week, was powered by Atlas Ventures and Northpond Ventures, and includes participating investors Hatteras Partners and Alexandria Venture Investments. SciNeuro Pharmaceuticals.

Marketing

Marketing In-Vivo Protein In-Vitro

Birinapant licensing; AvantGen, IGM pairs up for anti-SARS-CoV-2 antibodies; BeiGene, Novartis to co-dvelop Tislelizumab; Valo raises USD190 M; Bluebird Bio Spins-off

Delveinsight

JANUARY 12, 2021

Medivir, IGM Biosciences enters into an exclusive licensing agreement for Birinapant. Medivir AB has entered into an exclusive licensing agreement with IGM Biosciences to receive global, exclusive development rights for Birinapant. AvantGen Enters into a Licensing Agreement for its Anti-SARS-CoV-2 Antibodies with IGM Biosciences.

Licensing

Licensing Licensing Antibody Gene Therapy

Global Roundup: Overland Pharma Launches in China to Provide Access to Breakthrough Therapies

The Pharma Data

DECEMBER 9, 2020

OHMX.bio – Belgium-based OHMX.bio and Fujirebio Europe were awarded a €720,000 research grant from Flanders Innovation & Entrepreneurship (VLAIO) to develop a clinical in vitro diagnostics (IVD) platform incorporating third generation sequencing (TGS) technologies. A solution could be at hand with Overland Pharmaceuticals.

In-Vivo

In-Vivo In-Vitro Antibody Development

Eucure Biopharma and Chipscreen NewWay sign licence deal for YH008

Pharmaceutical Technology

FEBRUARY 28, 2023

Biocytogen Pharmaceuticals’ wholly owned subsidiary Eucure Biopharma and Shenzhen Chipscreen Biosciences’ holding subsidiary Chipscreen NewWay Biosciences have entered an exclusive licensing agreement for YH008, a bispecific antibody. It also activated tumour-infiltrating DCs and T cells in vivo pharmacodynamic studies.

In-Vivo

In-Vivo Antibody In-Vitro Licensing

Clinical Research Informer

Ginkgo Bioworks partners with WARF for new GD2 CAR T-cell therapies

Nuvectis Pharma receives IND approval from FDA for NXP900

Trending Sources

Betta to commercialise C4 Therapeutics’ CFT8919 in greater China

Blenrep Combination Extends Survival in Relapsed Multiple Myeloma

Could CRISPR cure HIV? US biotech Excision raises $60m to find out

Merck will assess Quris’ AI ‘patient-on-a-chip’ drug safety

AvantGen Announces Licensing of Its Anti-SARS-CoV-2 Antibodies to IGM Biosciences for COVID-19 Therapy Development

ViGeneron signs global collaboration agreement for ophthalmic gene therapy development

Separating the Hype from the Hyperbole Surrounding FDORA’s Alternatives to Animal Testing under the FD&C Act

Evusheld long-acting antibody combination recommended for approval in the EU for the pre-exposure prophylaxis (prevention) of COVID-19

Evusheld long-acting antibody combination approved in the EU for pre-exposure prophylaxis (prevention) of COVID-19 in a broad population

Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer

Innovative Companies Diving into The Neuro Market Ahead of 2021

Birinapant licensing; AvantGen, IGM pairs up for anti-SARS-CoV-2 antibodies; BeiGene, Novartis to co-dvelop Tislelizumab; Valo raises USD190 M; Bluebird Bio Spins-off

Global Roundup: Overland Pharma Launches in China to Provide Access to Breakthrough Therapies

Eucure Biopharma and Chipscreen NewWay sign licence deal for YH008

Stay Connected